WNT2 and non-small cell lung carcinoma: Moreover, a small molecule inhibitor 2,3,6-trisubstituted quinoxaline derivative, GDK-100,017, was found to inhibit cell proliferation of WNT2 overexpressing NSCLC cells and enhance their sensitivity to radiotherapy in a dose-dependent manner by targeting the canonical WNT pathway [61].